DALLAS, TX and New York, NY April 21, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma’s FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.
Read more »
DALLAS, TX and NEW YORK, NY April 19, 2010
Jeffrey Davis, President and Chief Executive Officer of ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, was recently interviewed by the Proactive Investors Group, an international financial media company. In the interview, Davis provides an overview of Access Pharma’s robust product pipeline, an update on the global rollout of its FDA-approved product MuGard, and discusses the Company’s ongoing multi-faceted approach to build value for shareholders.
Read more »
DALLAS, TX and NEW YORK, NY April 15, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it is collaborating with leading expert in oral mucositis (“OM”), Stephen T. Sonis, DMD, DMSc, Chief of the Division of Oral Medicine at the Dana Farber Cancer Institute and Program Director for Supportive Cancer Care at Clinical Assistance Programs, LLC (“CAP”), to further advance ongoing marketing and reimbursement efforts for MuGard. Together with Dr. Sonis, Access Pharma will develop a program to generate additional clinical data to further support the Company’s marketing and reimbursement initiatives surrounding the U.S. commercial launch of its lead product, MuGard – a FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Dr. Sonis will be the primary author on a study protocol aimed at obtaining specific data that will help further broaden the indication for MuGard and support reimbursement efforts geared towards enhancing payer uptake of MuGard. Any MuGard studies will run parallel with the product’s ongoing commercialization efforts.
Read more »
DALLAS, TX and NEW YORK, NY, April 13, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) announced that it has completed its first commercial scale production run of MuGard in North America at Accupac, Inc. manufacturing facilities outside Philadelphia. Access intends to use the initial batches of MuGard for pre-launch key institution evaluations, preliminary stock for select wholesalers and specialty distributors, and additional post-approval studies to be conducted in the U.S. pursuant to guidelines and protocols that are currently being developed. Accupac manufactures, fills and packages a wide range of consumer commodity, over-the-counter (OTC) and prescription (Rx) products for the world’s largest pharmaceutical and consumer products companies. Access’ MuGard is FDA-approved for the management of oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
Read more »
Digg!
Del.icio.us
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See